Pharmacy Podcast Network

In March of 2009, Institutional Pharmacy Technology marketing leader, Todd S. Eury, launched the Pharmacy Podcast Show. Over the years, the Pharmacy Podcast has accumulated over 67,000+ listeners and subscribers and is the most popular and downloaded podcast about the Pharmacy Industry. The Pharmacy Podcast Show transformed into the Pharmacy Podcast Network (PPN) in 2016 and will continue to collect the thought leading interviews with some of the most brilliant minds in Pharmacy with over 25 co-hosts. The PPN is a Digital Health Publication and Content Developing partner to the Pharmaceutical industry focusing on Specialty medications, pharmacy business supportive technologies, and industry trends. The PPN is dedicated to Specialty, Retail, Long-term Care, Micro-Chain, – Pharmacy Businesses, Patients, and Pharmacy Students with special content for each of these specific audiences. The PPN is the nation's largest network of podcasts dedicated to the pharmacy professional and industry insiders leading with our 25 co-hosts interviewing dynamic people in the pharmacy industry making a difference for our profession, customers, and patients. The definition of “Innovation” is: A new method, idea, product, or process. Processing, implementing, operating, or designing beyond the status-quo.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

NOVABAY PHARMACEUTICALS COLLABORATES WITH HARROW HEALTH’S IMPRIMISRX TO PROMOTE PRESCRIPTION AVENOVA

NovaBay Pharmaceuticals | July 20, 2021

news image

NovaBay Pharmaceuticals, Inc., a pharmaceutical firm focused on commercializing Avenova for the eye care market, has announced a collaboration with ImprimisRx, one of the nation's top ophthalmology-focused pharmaceutical companies, to promote prescription Avenova. ImprimisRx, a wholly-owned subsidiary of Harrow Health, Inc., will offer national sales, marketing, and distribution support for NovaBay's FDA-cleared 0.01% hypochlorous acid Avenova in 40 ml bottles. Avenova is a clinically ap...

Read More

OSTRICH PHARMA USA PRODUCES ANTIBODIES TO BLOCK THE VIRUS THAT CAUSES COVID-19

Business Wire: | April 01, 2020

news image

Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S. Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sciences at Kyoto Prefectural University and Co-CEO of Ostrich Pharma USA, has injected a genetically engineered pseudovirus into ostriches, and antibodies were purified from their eggs. These antibodie...

Read More

BUSINESS INSIGHTS

SIO2 MATERIALS SCIENCE AND DOOSAN CORPORATION ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE MARKET DEVELOPMENT IN ASIA

SiO2 Materials Science | December 27, 2021

news image

Doosan Corporation, founded in 1896, one of South Korea's largest diversified conglomerates, and SiO2 Materials Science, a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, announced an exclusive partnership to sell, market, and distribute SIO2's vial, syringes and blood collection tubes in Asia/Oceania. The partnership will focus initially on the pharmaceutical and diagnostics...

Read More

PHARMA TECH

MERCK DRIVES NEW INNOVATION & ADDS CAPACITY TO ADVANCE NEXT GENERATION ANTIBODY-DRUG CONJUGATE (ADC) THERAPIES

Merck | October 29, 2021

news image

Merck, a leading science and technology company, today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies. These initiatives underscore Merck's continued investment in novel modalities and support the company's efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. "ADCs have experienced remarkable growth, with commerci...

Read More
news image

BUSINESS INSIGHTS

NOVABAY PHARMACEUTICALS COLLABORATES WITH HARROW HEALTH’S IMPRIMISRX TO PROMOTE PRESCRIPTION AVENOVA

NovaBay Pharmaceuticals | July 20, 2021

NovaBay Pharmaceuticals, Inc., a pharmaceutical firm focused on commercializing Avenova for the eye care market, has announced a collaboration with ImprimisRx, one of the nation's top ophthalmology-focused pharmaceutical companies, to promote prescription Avenova. ImprimisRx, a wholly-owned subsidiary of Harrow Health, Inc., will offer national sales, marketing, and distribution support for NovaBay's FDA-cleared 0.01% hypochlorous acid Avenova in 40 ml bottles. Avenova is a clinically ap...

Read More
news image

OSTRICH PHARMA USA PRODUCES ANTIBODIES TO BLOCK THE VIRUS THAT CAUSES COVID-19

Business Wire: | April 01, 2020

Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S. Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sciences at Kyoto Prefectural University and Co-CEO of Ostrich Pharma USA, has injected a genetically engineered pseudovirus into ostriches, and antibodies were purified from their eggs. These antibodie...

Read More
news image

BUSINESS INSIGHTS

SIO2 MATERIALS SCIENCE AND DOOSAN CORPORATION ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE MARKET DEVELOPMENT IN ASIA

SiO2 Materials Science | December 27, 2021

Doosan Corporation, founded in 1896, one of South Korea's largest diversified conglomerates, and SiO2 Materials Science, a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, announced an exclusive partnership to sell, market, and distribute SIO2's vial, syringes and blood collection tubes in Asia/Oceania. The partnership will focus initially on the pharmaceutical and diagnostics...

Read More
news image

PHARMA TECH

MERCK DRIVES NEW INNOVATION & ADDS CAPACITY TO ADVANCE NEXT GENERATION ANTIBODY-DRUG CONJUGATE (ADC) THERAPIES

Merck | October 29, 2021

Merck, a leading science and technology company, today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies. These initiatives underscore Merck's continued investment in novel modalities and support the company's efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. "ADCs have experienced remarkable growth, with commerci...

Read More